Home › Agent Hub › Agent Tools › Part D coverage by drug › Jublia

Agent Tools

Jublia Part D coverage 2027

Jublia is a brand of efinaconazole. What agents check before quoting it: how many 2027 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.

Coverage at a glance

In 2027, 954 of 5,492 Medicare Part D and Medicare Advantage drug plans (17.4%) list Jublia on their formulary, across 23 of 286 formularies. The most common placement is tier 4 (852 plans, 89.3% of those covering it). 6 of the covering plans require prior authorization (0.6%), 0 step therapy and 0 a quantity limit.

What a 30-day fill costs

11 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $0, 11 of them $0; 943 charge coinsurance instead — median 27% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,400 in 2027, covered drugs cost $0 for the rest of the year.

What changed since 2026

2026: 1,011 of 5,496 plans covered it (18.4%); 2027: 954 of 5,492 (17.4%).

Of 4,367 plans offered in both years, 39 added it to the formulary and 33 dropped it.

Among plans covering it both years, 0 moved it to a higher tier and 0 to a lower one; 0 added prior authorization and 0 removed it.

Tier placement

By plan type

By carrier

By state

Medicare usage

Medicare Part D paid for 117,040 30-day fills of Jublia in 2024 for about 35,388 enrollees, at an average total cost of $1,008.57 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).

Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 10/08/2026). CMS formulary data.